Exelixis Inc (EXEL)

21.82
-0.02(-0.09%)
After Hours
21.89
+0.07(+0.32%)
- Real-time Data
  • Volume:
    3,196,377
  • Bid/Ask:
    21.45/22.00
  • Day's Range:
    21.67 - 22.08

EXEL Overview

Prev. Close
21.84
Day's Range
21.67-22.08
Revenue
1.16B
Open
22
52 wk Range
16.19-25.77
EPS
0.29
Volume
3,196,377
Market Cap
6.87B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,927,826
P/E Ratio
75.83
Beta
0.95
1-Year Change
-6.07%
Shares Outstanding
315,048,788
Next Earnings Date
Nov 04, 2021
What is your sentiment on Exelixis Inc?
or
Market is currently closed. Voting is open during market hours.

Exelixis Inc News

Exelixis Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuySell
SummaryStrong SellSellStrong BuyStrong BuyNeutral

Exelixis Inc Company Profile

Exelixis Inc Company Profile

Employees
773

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Read More
  • 🚀🚀🚀FDA approves Exelixis thyroid cancer treatment
    1
    • Dog
      0
      • Patricio, acaso vives en Valencia, España? Es que conozco a un Patricio Garnica x'D
        0
    • Exel was supposed to be a great investment. I hope it goes to 30 like expected
      0
      • Any update on this one?
        0
        • Great balance sheet, this stock seems quite undervalued! Just added some more to my portfolio at $19 :D
          1
          • Good report! I think time to buy!
            0
            • president and CEO are selling their shares right before earning report. ain't good
              0
              • Going to the place it belongs, up!
                0
                • Nothing, should be forgotten in any portfolio
                  1
                  • ok
                    0
                    • ANy hints on this drop today?
                      1
                      • Good entry here around 20 USD !!
                        0
                        • exel is going down.......buy put options as it rallies....that's the play on this stock @ this time
                          1
                          • exelixis is ******
                            0
                            • 23.50 will long it
                              0
                              • good choice
                                0
                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.